title: Drug interactions and pharmacogenomics in the treatment of breast cancer and depression.
authors.affiliation: Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 300 North Ingalls St., Bldg. 3A04, Ann Arbor, MI 48109-5419, USA. norahh@med.umich.edu
authors.forename: N Lynn
authors.initials: NL
authors.lastname: Henry
authors.forename: Vered
authors.initials: V
authors.lastname: Stearns
authors.forename: David A
authors.initials: DA
authors.lastname: Flockhart
authors.forename: Daniel F
authors.initials: DF
authors.lastname: Hayes
authors.forename: Michelle
authors.initials: M
authors.lastname: Riba
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001711:Biotransformation / Q000235:genetics; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D018270:Carcinoma, Ductal, Breast / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D003511:Cyclohexanols / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D003692:Delayed-Action Preparations; D003865:Major Depressive Disorder / Q000097:blood / Q000188:drug therapy*; D004347:Drug Interactions / Q000235:genetics; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D019584:Hot Flashes / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy / Q000523:psychology; D006801:Humans; D008875:Middle Aged; D010597:Pharmacogenetics; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D013629:Tamoxifen / Q000009:adverse effects* / Q000031:analogs & derivatives / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D016896:Treatment Outcome; D000069470:Venlafaxine Hydrochloride
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000928:Antidepressive Agents; D018931:Antineoplastic Agents, Hormonal; D003511:Cyclohexanols; D019389:Cytochrome P-450 CYP2D6; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D003692:Delayed-Action Preparations; D017367:Selective Serotonin Reuptake Inhibitors; D013629:Tamoxifen; D000069470:Venlafaxine Hydrochloride; C055492:4-hydroxy-N-desmethyltamoxifen